CODOX

None

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

This drug should be coded

None

None

None

The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.

This drug should NOT be coded

None

FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.

This drug should be coded

None

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

This drug should be coded

None

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

This drug should be coded

None

None

None

On March 29, 2018: The FDA approved use of Leukine (sargramostim) to increase survival in adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS). Leukine can help patients with H-ARS by facilitating recovery of bone marrow cells that develop into white blood cells that help fight off infections.

This drug should NOT be coded

None

None

Antineoplastic; vinca plant alkaloid; antimetabolite. FDA approved uses in ALL, Hodgkin's lymphoma, non-Hodgkin's lymphoma, neuroblastoma, rhabomyosarcoma, and Wilm's tumor.

This drug should be coded